Ligand-Binding Architecture of Human CB2 Cannabinoid Receptor: Evidence for Receptor Subtype-Specific Binding Motif and Modeling GPCR Activation

Chemistry and Biology

Volumn 15, Issue 11, 2008, Pages 1207-1219

  Pei, Ying ^a   Mercier, Richard W ^a   Anday, Jenine K ^a   Thakur, Ganesh A ^b   Zvonok, Alexander M ^b   Hurst, Dow ^c   Reggio, Patricia H ^c   Janero, David R ^b   Makriyannis, Alexandros ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

CHEMBIO; MOLNEURO; SIGNALING

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; LIGAND; MUTANT PROTEIN;

AFFINITY LABELING; AMINO ACID SEQUENCE; ARTICLE; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; PROTEIN BINDING; SITE DIRECTED MUTAGENESIS;

AFFINITY LABELS; AMINO ACID SEQUENCE; CELL LINE; DRUG DISCOVERY; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; MUTATION; PROTEIN BINDING; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SUBSTRATE SPECIFICITY;

EID: 56049101882     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2008.10.011     Document Type: Article

References (64)

1. Admiraal S.J., Meyer P., Schneider B., Deville-Bonne D., Janin J., and Herschlag D. Chemical rescue of phosphoryl transfer in a cavity mutant: a cautionary tale for site-directed mutagenesis. Biochemistry 40 (2001) 403-413
2. Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., and Struh K. Current Protocols in Molecular Biology (2006), J. Wiley and Sons, New Jersey
3. Ballesteros J.A., and Weinstein H. Integrated Methods for the Construction of Three Dimensional Models and Computational Probing of Structure Function Relations in G Protein-Coupled Receptors. In: Conn P.M., and Sealfon S.M. (Eds). Methods in Neuroscience Volume 25 (1995), Academic Press, San Diego 366-428
4. Barnett-Norris J., Hurst D.P., Buehner K., Ballesteros J.A., Guarnieri F., and Reggio P.H. Agonist alkyl tail interaction with cannabinoid CB1 receptor V6.43/I6.46 groove induces a helix 6 active conformation. Int. J. Quantum Chem. 88 (2002) 76-86
5. Barnett-Norris, J., Hurst, D.P., and Reggio, P.H. (2003). The influence of cannabinoid receptor second extracellular loop conformation on the binding of CP55940. In 2003 Symposium on the Cannabinoids, (Cornwall, Ontario: International Cannabinoid Research Society), p. 79.
6. Bouaboula M., Poinot-Chazel C., Marchand J., Canat X., Bourrie B., Rinaldi-Carmona M., Calandra B., Le-Fur G., and Casellas P. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor: involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 237 (1996) 704-711
7. Bramblett R.D., Panu A.M., Ballesteros J.A., and Reggio P.H. Construction of a 3D model of the cannabinoid CB1 receptor: determination of helix ends and helix orientation. Life Sci. 56 (1995) 1971-1982
8. Charalambous A., Yan G., Houston D.B., Howlett A.C., Compton D.R., Martin B.R., and Makriyannis A. 5′Azido-delta-8-THC: a novel photoaffinity label for the cannabinoid receptor. J. Med. Chem. 35 (1992) 3076-3079
9. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Kuhn P., Weis W.I., Kobilka B.K., and Stevens R.C. High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 318 (2007) 1258-1265
10. Chin C.N., Lucas-Lenard J., Abadji V., and Kendall D.A. Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J. Neurochem. 70 (1998) 366-373
11. De-Lean A., Stadel J.M., and Lefkowitz R.J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J. Biol. Chem. 255 (1980) 7108-7117
12. Deng H., Gifford A.N., Zvonok A.M., Cui G., Li X., Fan P., Deschamps J.R., Flippen-Anderson J.L., Gatley S.J., and Makriyannis A. Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor. J. Med. Chem. 48 (2005) 6386-6392
13. Dhawan J., Deng H., Gatley S.J., Makriyannis A., Akinfeleye T., Bruneus M., Dimaio A.A., and Gifford A.N. Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233. Synapse 60 (2006) 93-101
14. Farrens D.L., Altenbach C., Yang K., Hubbell W.L., and Khorana H.G. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274 (1996) 768-770
15. Fride E., Foox A., Rosenberg E., Faigenboim M., Cohen V., Barda L., Blau H., and Mechoulam R. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Eur. J. Pharmacol. 461 (2003) 27-34
16. 2+ channel current. Am. J. Physiol. 276 (1999) H2085-H2093
17. Gouldson P., Calandra B., Legoux P., Kerneis A., Rinaldi-Carmona M., Barth F., Le Fur G., Ferrara P., and Shire D. Mutational analysis and molecular modeling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor. Eur. J. Pharmacol. 401 (2000) 17-25
18. Guo Y., Abadji V., Morse K.L., Fournier D.J., Li X., and Makriyannis A. (-)-11-Hydroxy-7′-isothiocyanato-1′,1′-dimethylheptyl-delta-8-THC: a novel, high-affinity irreversible probe for the cannabinoid receptor in brain. J. Med. Chem. 37 (1994) 3867-3870
19. Hassan S.A., Mehler E.L., and Weinstein H. Structure calculation of protein segments connecting domains with defined secondary structure: A simulated annealing Monte Carlo combined with biased scaled collective variables technique. In: Gan H.H. (Ed). Computational Methods for Macromolecules: Challenges and Applications Volume 24 (2002), Springer-Verlag, New York 197-231
20. Hurst D.P., Lynch D.L., Barnett-Norris J., Hyatt S.M., Seltzman H.H., Zhong M., Song Z.H., Nie J., Lewis D., and Reggio P.H. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyraxole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol. Pharmacol. 62 (2002) 1274-1287
21. Jagerovic N., Fernandez-Fernandez C., and Goya P. CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications. Curr. Top. Med. Chem. 8 (2008) 205-230
22. Javitch J.A., Fu D., Liapakis G., and Chen J. Constitutive activation of the β2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J. Biol. Chem. 272 (1997) 18546-18549
23. Jensen A.D., Guarnieri F., Rasmussen S.G., Asmar F., Ballesteros J.A., and Gether U. Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the β2-adrenergic receptor mapped by site-selective fluorescent labeling. J. Biol. Chem. 276 (2001) 9279-9290
24. Lan R., Liu Q., Fan P., Lin S., Fernendo S.R., McCallion D., Pertwee R., and Makriyannis A. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. 42 (1999) 769-776
25. Lagerström M.C., and Schiöth H.B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7 (2008) 339-357
26. Leff P. The two-state model of receptor activation. Trends Pharmacol. Sci. 16 (1995) 89-97
27. Lin S.W., and Sakmar T.P. Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry 35 (1996) 11149-11159
28. Mackie K., Lai Y., Westenbroek R., and Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15 (1995) 6552-6561
29. Malan Jr. T.P., Ibrahim M.M., Lai J., Vanderah T.W., Makriyannis A., and Porreca F. CB2 cannabinoid receptor agonists: pain relief without psychoactive effects?. Curr. Opin. Pharmacol. 3 (2003) 62-67
30. Marriott K.S., and Huffmann J.W. Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. Curr. Top. Med. Chem. 8 (2008) 187-204
31. Mavromoustakos T., Yang D.P., Broderick W., Fournier D., and Makriyannis A. Small angle X-ray diffraction studies on the topography of cannabinoids in synaptic plasma membranes. Pharmacol. Biochem. Behav. 40 (1991) 547-552
32. Mavromoustakos T., Yang D.P., and Makriyannis A. Small angle X-ray diffraction and differential scanning calorimetric studies on O-methyl-(-)-delta-8-tetrahydrocannabinol and its 5′ iodinated derivative in membrane bilayers. Biochim. Biophys. Acta 1237 (1995) 183-188
33. Monory K., Tzavara E.T., Lexime J., Ledent C., Parmentier M., Borsodi A., and Hanoune J. Novel, not adenyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem. Biophys. Res. Commun. 292 (2002) 231-235
34. Morse K.L., Fournier D.J., Li X., Grzybowska J., and Makriyannis A. A novel electrophilic high affinity irrreversible probe for the cannabinoid receptor. Life Sci. 56 (1995) 1957-1962
35. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
36. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Le Trong I., Teller D.C., Okada T., Stenkamp R.E., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 (2000) 739-745
37. Palmer S.L., Thakur G.A., and Makriyannis A. Cannabinegic ligands. Chem. Phys. Lipids 121 (2002) 3-19
38. 2+ channels in a neuronal expression system. Mol. Pharmacol. 49 (1996) 707-714
39. Park J.H., Scheerer P., Hofmann K.P., Choe H.W., and Ernst O.P. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454 (2008) 183-187
40. Peracchi A. Enzyme catalysis: removing chemically "essential" residues by site-directed mutagenesis. Trends Biochem. Sci. 26 (2001) 497-503
41. Picone R.P., Fournier D.J., and Makriyannis A. Ligand based structural studies of the CB1 cannabinoid receptor. J. Pept. Res. 60 (2002) 348-356
42. Picone R.P., Khanolkar A.D., Xu W., Ayotte L.A., Thakur G.A., Hurst D.P., Abood M.E., Reggio P.H., Fournier D.J., and Makriyannis A. (-)-7′-Isothiocyanato-11-hydroxy-1′,1′-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol. Pharmacol. 68 (2005) 1623-1635
43. Poso A., and Huffman J.W. Targeting the cannabinoid CB2 receptor: modeling and structural determinants of CB2 selective ligands. Br. J. Pharmacol. 153 (2008) 335-346
44. Raitio K.H., Salo O.M., Nevalainen T., Poso A., and Jarvinen T. Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands. Curr. Med. Chem. 12 (2005) 1217-1237
45. Reggio P.H. Computational methods in drug design: modeling G protein-coupled receptor monomers, dimers, and oligomers. AAPS J. 8 (2006) E322-E336
46. Reggio P.H., Panu A.M., and Miles S. Characterization of a region of steric interference at the cannabinoid receptor using the active analog approach. J. Med. Chem. 36 (1993) 1761-1771
47. Rhee M.H. Functional role of serine residues of transmembrane dopamin VII in signal transduction of CB2 cannabinoid receptor. J. Vet. Sci. 3 (2002) 185-191
48. Rhee M.H., and Kim S.K. SR144528 as inverse agonist of CB2 cannabinoid receptor. J. Vet. Sci. 3 (2002) 179-184
49. Rhee M.H., Bayewitch M., Avidor-Reiss T., Levy R., and Vogel Z. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isoenzymes. J. Neurochem. 71 (1998) 1525-1534
50. Sali A., and Blundell T.L. Comparative protein modeling by satisfaction of spatial restraints. J. Mol. Biol. 234 (1993) 779-815
51. Samama P., Cotecchia S., Costa T., and Lefkowitz R.J. A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268 (1993) 4625-4636
52. Shen C.P., Xiao J.C., Armstrong H., Hagmann W., and Fong T.M. F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist. Eur. J. Pharmacol. 531 (2006) 41-46
53. Shi L., Liapakis G., Xu R., Guarnieri F., Ballesteros J.A., and Javitch J.A. β2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J. Biol. Chem. 277 (2002) 40989-40996
54. Shire D., Calandra B., Delpech M., Dumont X., Kaghad M., Le Fur G., Caput D., and Ferrara P. Structural features of the central cannabinoid CB1 receptor involved in binding of the specific CB1 antagonist SR 141716A. J. Biol. Chem. 271 (1996) 6941-6946
55. Song Z.H., and Bonner T.I. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol. Pharmacol. 49 (1996) 891-896
56. Tahtaoui C., Balestre M.N., Klotz P., Rognan D., Barberis C., Mouillac B., and Hibert M. Identification of the binding sites of the SR49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfhydryl-reactive ligands and cysteine mutants as chemical sensors. J. Biol. Chem. 278 (2003) 40010-40019
57. Tao Q., and Abood M.E. Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J. Pharmacol. Exp. Ther. 285 (1998) 651-658
58. Tao Q., McAllister S.D., Andreassi J., Nowell K.W., Cabral G.A., Hurst D.P., Bachtel K., Ekman M.C., Reggio P.H., and Abood M.E. Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity. Mol. Pharmacol. 55 (1999) 605-613
59. Tian X., Guo J., Yao F., Yang D.P., and Makriyannis A. The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer. J. Biol. Chem. 280 (2005) 29788-29795
60. Vemuri V.K., Janero D.R., and Makriyannis A. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol. Behav. 93 (2008) 671-686
61. 1-adrenergic G-protein-coupled receptor. Nature 454 (2008) 486-491
62. Xu W., Filppula S., Mercier R., Yaddanapudi S., Pavlopoulos S., Cai J., Pierce W.M., and Makriyannis A. Purification and mass spectroscopic analysis of human CB1 cannabinoid recpetor functionality expressed using the baculovirus system. J. Pept. Res. 66 (2005) 138-150
63. Zhang R., Hurst D.P., Barnett-Norris J., Reggio P.H., and Song Z.H. Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template. Mol. Pharmacol. 68 (2005) 69-83
64. Zvonok N., Pandarinathan L., Williams J., Johnston M., Karageorgos I., Janero D.R., Krishnan S.C., and Makriyannis A. Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis. Chem. Biol. 15 (2008) 854-862